NCT06650566

Study of LM-299 in Subjects Advanced Malignant Tumors

A Phase I/II, Open-label, Dose Escalation and Dose Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of LM-299 Injection as Monotherapy or in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 108 (estimated)
• Sponsor: LaNova Medicines Limited · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-299 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explorethe recommended dose for expansion (RDE) in patients with advanced solid tumours.. For Phase II Dose Expansion Stage, to assess the antitumor activity of LM-299 in patients with various advanced solid tumors.

Conditions

• Malignant Tumors

Interventions

Type	Name	Description
DRUG	LM-299	Q2W/Q3W,Intravenous Drip

Timeline

• Start date: 2024-10-09
• Primary completion: 2026-12-01
• Completion: 2027-07-01
• First posted: 2024-10-21
• Last updated: 2025-05-02

Locations

6 sites across 2 countries: Australia, China